Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01754025 · ClinicalTrials.gov registry record
INHERIT EGFR - Studying Germline EGFR Mutations
A clinical trial of Lung Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 121
- Enrollment target
- 2
- Study locations
NCT01754025 is a study of Lung Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 121 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01754025, a study of Lung Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 121 participants
- Enrollment target
- 2
- Study locations
Study Summary
Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung cancer. It has been recently found that a small number of families have an inherited (passed from parent to child) change in one of their genes that may contribute to an increased tendency to develop lung cancers, even in never smokers. In some lung cancer patients this gene, called "EGFR", contains a DNA change known as an "inherited EGFR mutation". Early data indicate that these inherited EGFR mutations may be associated with an increased risk of lung cancer. So far, only a small number of families have been found to carry inherited EGFR mutations. For this reason the risk of lung cancer associated with inherited EGFR mutations is not well understood. Understanding the risk may help investigators find ways of detecting lung cancer sooner or reducing the risk of developing lung cancer. It was recently discovered that lung cancer patients who are found to carry one rare EGFR mutation in their cancer cells, called "T790M", have an increased risk of carrying an inherited EGFR mutation in their normal cells as well. This represents a new strategy for finding individuals and families carrying inherited EGFR mutations. This research study is designed to find cancer patients whose tumors have this EGFR mutation, T790M, to find out if they also have an inherited EGFR mutation. Subjects will not have to undergo a biopsy to participate in this research study. Investigators will collect a saliva specimen from patients with a T790M in their cancer to find out if they also have an inherited EGFR mutation. Study participants found or known to carry an inherited EGFR mutation will have the option of offering their close relative the opportunity to also participate in this study. Close relatives can consider testing to see if they also carry the inherit
Conditions Studied
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2012-12-28 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01754025
The ClinicalTrials.gov registry entry for NCT01754025 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01754025 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01754025 about?
NCT01754025 is a clinical study titled "INHERIT EGFR - Studying Germline EGFR Mutations". Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung cancer. It has been recently found that a small number of families have ...
What is the current status of trial NCT01754025?
This trial is currently active not recruiting. The enrollment target is 121 participants. The study started on 2012-12-28. Estimated completion is 2029-12-31.
What conditions does trial NCT01754025 study?
This clinical trial studies the following conditions: Lung Cancer.
Who is sponsoring clinical trial NCT01754025?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01754025 being conducted?
This trial has 2 study locations across Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.